A US Food and Drug Administration (FDA) advisory panel has voted overwhelmingly against a new drug application (NDA) for intranasal carbetocin (Levo Therapeutics Inc.), intended to treat symptoms associated with Prader-Willi Syndrome (PWS). In a 12 to 1 vote on…
Read More
Genome of obese Ossabaw pig could provide new insights into human obesity
Mapping of the complete genome of the obesity-prone Ossabaw pig gives new hope for further insights into human obesity and associated diseases. For the first time in history, researchers at DTU Bioengineering and DTU Health Tech in collaboration with researchers…
Read More
Pandemic Adds More Weight to Burden of Obesity in Children
Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. American children gained a lot of weight in the last year, setting a dangerous trajectory towards metabolic disease that requires urgent policy change, according to a…
Read More
NHS data reveals UK obesity hotspots
We use your sign-up to provide content in ways you’ve consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info…
Read More
Novel Colonic Agonist Formulation Promising for Obesity
NEW YORK (Reuters Health) – A colonic release formulation of medium-chain fatty acids (MFCA) curbed appetite and boosted levels of the anorexigenic hormone PYY in a small placebo-controlled crossover trial involving obese adults. “We have shown that two nutrient-sensing receptors,…
Read More
Link between obesity and COVID-19 may not be what it seems
Obesity is frequently cited as a risk factor for severe COVID-19, but the role of weight bias and discrimination in that risk demands further investigation, according to Dr. Yoni Freedhoff, an associate professor of family medicine at the University of…
Read More
Semaglutide Boosts Weight Loss Following Endoscopic Gastroplasty
Combining minimally invasive endoscopic sleeve gastroplasty (ESG) with a weekly injection of the glucagon-like peptide-1 (GLP-1) agonist semaglutide (Ozempic, Novo Nordisk) leads to significantly greater weight loss than ESG alone in patients with diabetes and excess weight who are not…
Read More
Water-Soluble Vitamin D: Better for Those With Malabsorption?
A new oral formulation of vitamin D3 — calcifediol (25-hydroxyvitamin D3, 25(OH)D3) — is better absorbed by people with obesity or intestinal malabsorption due to a variety of reasons, making it much more effective at treating vitamin D deficiency in…
Read More
Study shows new obesity treatment semaglutide causes similar weight loss across different age groups
The STEP trials published over the past year have established the efficacy and safety of semaglutide in treating patients with obesity. A new study analysing the effects of this treatment in different age groups presented at this year’s European Congress…
Read More
Heart disease and obesity driven by liver function – new study
How susceptible we are to obesity and heart disease could be determined by our livers, a new study has revealed. Using a sample of over 700,000 individuals, scientists from Brunel University London and Imperial College London found that heart disease…
Read More